Immunome Inc.
04/30/2024 | Press release | Distributed by Public on 04/30/2024 14:02
Management Change/Compensation - Form 8-K
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April 24, 2024, Bob Lapetina notified Immunome, Inc. (the "Company") that he will be resigning from his positions as the Company's Vice President, Finance, Corporate Controller, and principal accounting officer to pursue other opportunities. The effective date of Mr. Lapetina's resignation will be May 10, 2024. Mr. Lapetina's resignation is not the result of any disagreement with the Company.
Appointment of Mr. Rosett as Principal Accounting Officer
On April 30, 2024, the Company's board of directors appointed Max Rosett, in addition to his other titles, as the Company's principal accounting officer effective immediately upon the effectiveness of Mr. Lapetina's resignation.
Mr. Rosett, age 34, has served as the Company's Interim Chief Financial Officer, EVP, Operations and principal financial officer since December 2023, and Senior Vice President, Operations since October 2023. Before joining the Company, Mr. Rosett held positions of increasing responsibility with Morphimmune, Inc. from January 2022 until October 2023, last serving as Morphimmune Inc.'s Acting Chief Operating Officer from March 2022 until October 2023. Mr. Rosett also served as Principal at Research Bridge Partners, a life science investment firm, from March 2021 until October 2023. He was previously Director of Data Science at Research Bridge Partners from February 2018 to February 2021. He has also worked as an engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.
Mr. Rosett has not entered into any material plan, contract or arrangement with the Company in connection with his appointment as the Company's principal accounting officer.
There are no family relationships between Mr. Rosett and any of the Company's current or former directors or executive officers. Mr. Rosett is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended.